John Varga

The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial

Richard S. Henry, M. Suarez‐Almazor, B. Levis, 2021, Trials.

There is a need for new systemic sclerosis subset criteria. A content analytic approach

Shervin, M. Baron, A. Gabrielli, 2018, Scandinavian journal of rheumatology.

Essential roles for early growth response transcription factor Egr-1 in tissue fibrosis and wound healing.

S. Bhattacharyya, D. Melichian, T. Mustoe, 2009, The American journal of pathology.

2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

M. Vonk, R. Naden, Y. Allanore, 2013, Arthritis and rheumatism.

Minimally important difference in diffuse systemic sclerosis: results from the d-penicillamine study

Richard W. Martin, R. Hays, M. Mayes, 2006, Annals of the rheumatic diseases.

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

R. Elashoff, R. Elashoff, M. Roth, 2007, American journal of respiratory and critical care medicine.

Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients

Richard S. Henry, M. Suarez‐Almazor, D. Rice, 2020, Journal of psychosomatic research.

A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease.

S. Jimenez, J. Varga, R. Steiner, 1998, The Journal of rheumatology.